The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete. | |||||||||||||||||
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 13F FORM 13F INFORMATION TABLE |
|
COLUMN 1 | COLUMN 2 | COLUMN 3 | COLUMN 4 | COLUMN 5 | COLUMN 6 | COLUMN 7 | COLUMN 8 | ||||
VALUE | SHRS OR | SH/ | PUT/ | INVESTMENT | OTHER | VOTING AUTHORITY | |||||
NAME OF ISSUER | TITLE OF CLASS | CUSIP | (x$1000) | PRN AMT | PRN | CALL | DISCRETION | MANAGER | SOLE | SHARED | NONE |
23andMe Holding Co. | COM CL A | 90138Q108 | 8,183 | 700,000 | SH | SOLE | 700,000 | 0 | 0 | ||
Aclaris Therapeutics, Inc. | COM | 00461U105 | 22,095 | 1,258,243 | SH | SOLE | 1,258,243 | 0 | 0 | ||
ALX Oncology Holdings Inc. | COM | 00166B105 | 12,642 | 231,200 | SH | SOLE | 231,200 | 0 | 0 | ||
BCTG Acquisition Corp. | COM | 05492W103 | 4,552 | 400,000 | SH | SOLE | 400,000 | 0 | 0 | ||
Cullinan Oncology, Inc. | COM | 230031106 | 70,334 | 2,731,410 | SH | SOLE | 2,731,410 | 0 | 0 | ||
FS Development Corp. II | COM CL A | 30318F100 | 6,013 | 602,500 | SH | SOLE | 602,500 | 0 | 0 | ||
Gemini Therapeutics, Inc. | COM | 36870G105 | 15,755 | 2,435,125 | SH | SOLE | 2,435,125 | 0 | 0 | ||
Helix Acquisition Corp. | COM CL A | G4444C102 | 2,588 | 250,000 | SH | SOLE | 250,000 | 0 | 0 | ||
Hims & Hers Health, Inc. | COM CL A | 433000106 | 11,510 | 1,056,922 | SH | SOLE | 1,056,922 | 0 | 0 | ||
Kinnate Biopharma Inc. | COM | 49705R105 | 20,370 | 875,001 | SH | SOLE | 875,001 | 0 | 0 | ||
Lucira Health, Inc. | COM | 54948U105 | 3,220 | 485,000 | SH | SOLE | 485,000 | 0 | 0 | ||
Nurix Therapeutics, Inc. | COM | 67080M103 | 11,979 | 451,522 | SH | SOLE | 451,522 | 0 | 0 | ||
Pharvaris N.V. | COM | N69605108 | 6,784 | 364,142 | SH | SOLE | 364,142 | 0 | 0 | ||
Population Health Investment Co., Inc. | UNIT | G71716123 | 9,744 | 960,000 | SH | SOLE | 960,000 | 0 | 0 | ||
Quantum-Si Incorporated | COM CL A | 74765K105 | 28,714 | 2,342,061 | SH | SOLE | 2,342,061 | 0 | 0 | ||
Relay Therapeutics, Inc. | COM | 75943R102 | 14,636 | 400,000 | SH | SOLE | 400,000 | 0 | 0 | ||
Research Alliance Corp. II | COM CL A | 760873109 | 5,070 | 500,000 | SH | SOLE | 500,000 | 0 | 0 |